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ZIKV-induced cell death. We show that this colorimet-
ric assay quantifies ZIKV infection over a broad range of 
viral dilutions in both monkey and human cells. It allows 
to determine inhibitory activities of antivirals that block 
ZIKV or to define the neutralizing antibody titers of ZIKV 
antisera. This MTT-based ZIKV detection assay can be 
evaluated by naked eye or computational tools, has a broad 
linear range, does not require large equipment or costly rea-
gents, and thus represents a promising alternative to anti-
body-based assays, in particular in resource-poor settings. 
We propose to use this simple, fast, and cheap method for 
quantification of ZIKV neutralizing antibodies and testing 
of antiviral compounds.
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Introduction
Since the first recognized large outbreak of ZIKV in Micro-
nesia in 2007, the virus spread rapidly and has now caused 
a major epidemic with an estimated number of more than 
1  million infected individuals in Brazil [1–3]. Although 
most infections are subclinical or mild, congenital ZIKV 
infection may result in severe birth defects, such as micro-
cephaly [4]. In addition, ZIKV infection is suspected to 
be associated with Guillain–Barre syndrome in adults [5]. 
Today, neither a protective vaccine nor a specific antiviral 
therapy is available to prevent or cure ZIKV infections. The 
virus is mainly transmitted by mosquitos, but congenital, 
perinatal, and sexual modes of transmission have also been 
described [6]. ZIKV is a flavivirus that has a positive-sense 
single-stranded RNA genome and is surrounded by a lipid 
bilayer which makes it susceptible to, e.g., alcoholic disin-
fectants [7].
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ZIKV diagnosis is based on direct amplification of viral 
RNA from patient material using “in house” or commer-
cially available RT-PCR assays [8–10]. Serological binding 
assays have also been approved but are often restricted to 
reference laboratories and have limitations, because ZIKV 
IgM and IgG antibodies are cross-reactive with other flavi-
viruses. Particularly, dengue virus circulating in the same 
areas, and the prodromi and acute clinical symptoms are 
similar as in ZIKV infection [10–13]. Thus, positive sero-
logical tests should be confirmed by virus neutralization 
assays in cell culture. One widely used assay is the plaque 
reduction neutralization test (PRNT) which is based on the 
capability of flaviviruses to cause formation of plaques in 
cell monolayers [10, 14]. This cytopathic effect (CPE) can 
be observed directly in cell culture or after live cell stain-
ing. Alternatively, infected cells can also be visualized by 
immunostaining with virus-specific antisera or monoclo-
nal antibodies. However, regardless of the method of visu-
alization, in PRNT, plaques are usually counted manually. 
Quantification of infected cells is also routinely performed 
by immunostaining to study, e.g., viral tropism or the effect 
of antiviral compounds [15, 16]. Here, infected cells are 
quantified by detection of viral antigen by flow cytometry 
or ELISA [15, 17]. These assays are time-consuming and 
require specific equipment like a flow cytometer or micro-
plate readers.
In this study, we describe a simple, fast, cheap, and 
robust assay to measure ZIKV infectivity and its inhibi-
tion by antisera or antivirals. The assay is based on the 
colorimetric detection of live cells using the tetrazolium 
salt MTT. Live cells reduce the yellow MTT solution by 
the NAD(P)H-dependent oxidoreductase system resulting 
in the formation of insoluble purple formazan crystals [18, 
19]. Vice versa, dead cells or cells with impaired metabo-
lism do not reduce MTT. Since ZIKV is able to cause cyto-
pathic effects in cell culture, infected cells die which results 
in a decreasing production of formazan crystals. We here 
show that the MTT-based cell viability assay allows quanti-
fication of ZIKV infectivity and its inhibition by interferon 
or patient sera. The assay can be evaluated by naked eye, 
has a broad linear range, does not require expensive equip-
ment or costly reagents, and thus represents an interesting 
alternative for ZIKV detection, in particular in resource-
poor environment.
Materials and methods
Cells, viruses, and reagents
Vero E6 cells  (ATCC® CRL-1586™), used for propagation 
and infection with ZIKV, were grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 2.5% 
heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 
units/ml penicillin, 100 µg/ml streptomycin, 1 mM sodium 
pyruvate, and non-essential amino acids (Sigma #M7145) 
at 37 °C in a 5%  CO2 humidified incubator. Human oste-
osarcoma (HOS) cells (NIH AIDS Reagent Program 
#3942) were grown in DMEM supplemented with 10% 
heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 
units/ml penicillin, and 100  µg/ml streptomycin. ZIKV 
strain MR766 was isolated in 1947 from a sentinel rhe-
sus macaque. FB-GWUH-2016 is a ZIKV strain that was 
isolated in 2016 from a fetal brain with severe abnormali-
ties [20]. The FB-GWUH-2016 stock used in this study 
was passaged two times on Vero E6 cells. Recombinant 
interferon-α (IFN-α) was purchased from pbl assay science 
(#11101-1).
Virus propagation
Virus was propagated by inoculation of 70% confluent Vero 
E6 cells in T175 cell culture flasks for 2 h in 5 ml medium. 
Subsequently, 40  ml fresh medium was added and the 
cells cultured for 3 to 5 days. Cytopathic effect (CPE) was 
monitored by light microscopy and virus was harvested 
when 70% of the cells detached due to CPE. Supernatant 
was taken, centrifuged for 3 min at 1,300 rpm, before virus 
stocks were aliquoted and stored at −80 °C.
MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphe-
nyl-2H-tetrazolium bromide) assay
After incubation of Vero E6 or HOS cells with or without 
virus for the length of the according experiment, 20 µl of 
MTT solution (5 mg/ml in PBS) was added to 200 µl cells. 
Following a 3  h incubation time at 37 °C, the cell-free 
supernatant was discarded and formazan crystals were dis-
solved in 100 µl of a 1:2 mixture of dimethyl sulfoxide and 
ethanol. Absorption was measured at 490 nm and baseline 
corrected at 650 nm using a VMax Kinetic ELISA micro-
plate reader (Molecular Devices). To determine infection 
rates, sample values were subtracted from untreated control 
and untreated control set to 100%. Error bars are standard 
deviations of triplicates.
CellTiter-Glo® Luminescent Cell Viability Assay
CellTiter-Glo® Luminescent Cell Viability Assay (Promega 
#G7571) was performed according to the manufacturer’s 
instructions. Briefly, medium was removed from the cells, 
and 50  µl PBS and 50  µl of reagent were added. After a 
10 min incubation, luminescence was measured in a Orion 
II Microplate Luminometer (Titertek Berthold).
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Cell-based Zika virus immunodetection assay
Immunodetection of ZIKV-infected cells was done as 
described [17]. Cells were rinsed with PBS, fixed for 
20  min at room temperature with 4% paraformaldehyde, 
permeabilized with cold methanol for 5  min at 4 °C, and 
washed with PBS. Next, cells were incubated with anti-
flavivirus mouse antibodies 4G2 from B lymphocyte hybri-
doma cells  (ATCC® HB-112™) (1:100) in PBS containing 
10% (v/v) FCS and 0.3% (v/v) Tween20 for 1 h at 37 °C. 
Following three times of washing with PBS containing 
0.3% (v/v) Tween20, cells were incubated with a HRP-cou-
pled anti-mouse antibody (1:20,000) (Thermo Fisher Sci-
entific #A16066) for 1 h at 37 °C. Next, cells were washed 
four times and TMB substrate was added. After 5  min 
of room temperature incubation, reaction was stopped 
with 0.5  M sulfuric acid. Absorption was measured at 
450 nm and baseline corrected at 650 nm using an ELISA 
microplate reader. Error bars are standard deviations of 
triplicates.
Patient sera
ZIKV-specific antisera were obtained from the reference 
collection of the WHO Collaborating Centre for Arbovirus 
and Hemorrhagic Fever Reference and Research, Hamburg, 
Germany [21]. Anti-ZIKV IgG and IgM titers were deter-
mined by indirect immunofluorescence assay (IIFA) using 
Vero E6 cells and ZIKV strain MR766. In brief, infected 
cells were spread onto slides, air dried, and fixed in ace-
tone. Serum samples were serially diluted in phosphate-
buffered saline (PBS) starting with an initial dilution of 
1:10, added to the cells, and incubated for 90 min at 37 °C. 
After washing with PBS, slides were incubated with fluo-
resceine isothiocyanate-labeled rabbit anti-human IgG and 
IgM antibodies at 37 °C for 25 min. IgG titers or IgM titers 
of 1:20 or more were considered positive.
Control antisera and antisera containing antibodies 
against DENV and TBEV were derived from the Insti-
tute of Virology, Ulm. Qualitative detection of antibod-
ies against DENV and TBEV was performed by ELISA 
according to the manufacturer’s instructions (Dengue 
Virus IgG DxSelect™ (EL1500G) Focus Diagnostics; 
Dengue IgM capture ELISA (01PE20) Panbio; TBE IgG/
IgM ELISA (EC117.00) Sekisui Diagnostics/Virotech). All 
sera were tested for cytotoxicity on Vero cells and were not 
toxic at concentrations of 1% (v/v).
MTT based neutralization assay
6,000 Vero E6 cells were seeded per 96 well in 100  µl 
medium and cultured overnight. For infection,  106  TCID50/
ml of ZIKV virus was incubated at room temperature with 
PBS or with 0.08, 0.16, 0.31, 0.63, 1.25, 2.50, 5, and 10% 
(v/v) heat-inactivated serum samples for 90  min. Cell 
medium was replaced by 180 µl fresh medium, and 20 µl of 
the ZIKV-serum mix was added in triplicates. 4 day post-
inoculation, infection was measured by MTT assay.
PRNT assay
6,000 Vero E6 cells were seeded in 96-well plates the 
day before the experiment. The patient sera/antisera were 
titrated twofold in medium from 1:20 to 1:163,840 and 
incubated with 100 PFU/ml ZIKV MR766 for 60  min at 
37 °C. Next, 100 µl of the ZIKV/serum mix was added to 
100 µl cells in triplicates and cells were monitored micro-
scopically. Five day post-inoculation, cytopathic effects 
were best visible, and the lowest titer that inhibited ZIKV 
infection was determined.
Statistics
Z’ factor was calculated as described [22, 23] and MTT 
assay-derived  EC50s and titers were determined by Graph-
Pad Prism (GraphPad Software, Inc.)
Results
To study whether the MTT-based cell viability assay allows 
quantification of ZIKV infectivity, we monitored the forma-
tion of the virus-induced cytopathic effect (CPE) in Vero 
E6 cells that were infected with serial tenfold dilutions of 
the MR766 strain [24]. The applied ZIKV stock had an 
infectious dose of 1.6 × 107  TCID50/ml and a genome copy 
number of ~1 × 1010 /ml [7]. Cells were monitored micro-
scopically, and already after 2 days, plaques and detached 
cells were observed in wells infected with the two high-
est virus concentrations (not shown). After 4 days, a pro-
nounced CPE was observed in wells infected with  101 to 
 105-fold dilutions of the virus, and at the  106-dilution still 
single plaques could be detected (examples shown in Fig. 
S1A). Next, 20 µl of a MTT solution was added to cells at 
day 4 post-inoculation. Following a 3 h incubation at 37 °C, 
the supernatants which contain detached and dead cells 
were discarded, and the formazan crystals formed by adher-
ent live cells were solubilized in 100  µl of a 1:2 mixture 
of dimethyl sulfoxide and ethanol, which also inactivates 
virus [7]. Visual examination of the microtiter plate showed 
that wells containing uninfected cells or cells that were 
inoculated with viral dilutions exceeding  105 contained 
a dark purple solution (Fig. S1B). In contrast, wells that 
were infected with a dilution of the virus stock that causes 
a pronounced CPE (Fig. S1A) contained a clear transpar-
ent solution (Fig. S1B). Inoculation with  102–105 dilutions 
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of the virus resulted in a gradually decreased plaque for-
mation (Fig. S1A) that correlated with increased color 
intensity (Fig. S1B). Thus, the development of formazan 
crystals in live cells allows for an indirect detection of the 
ZIKV-infected cells.
We next quantified formazan formation in cell cultures 
that were infected for 1–8 days with serial dilutions of the 
ZIKVMR766 stock. Color development was determined 
by recording the absorbance at 490 nm (OD, optical den-
sity) using an ELISA microplate reader (Fig.  1a). At day 
1, only the highest virus dose caused a slight reduction of 
the OD, as compared to the uninfected control (Fig. 1a). At 
days 2 to 8, the ODs increased with increasing viral dilu-
tions. (Fig. 1a). We next calculated the Z’ factor as a meas-
ure of statistical effect size which is used to validate the 
quality of high-throughput assays [22]. The Z’ factor was, 
on average, 0.77 demonstrating an excellent assay perfor-
mance. The best dose-dependent correlation was observed 
at day 3 (R2 = 0.90) (Fig.  1a and Fig. S2). Microscopic 
evaluation of cells infected with viral dilutions of  101 to 
 104 revealed pronounced plaque formation at day 6 to 8 
(not shown), and consequently, OD values close to zero 
(Fig. 1a). Thus, quantification of live cells by MTT assay is 
an indirect measurement for ZIKV infectivity. Due to ongo-
ing cell growth, ODs of uninfected cells increased from day 
1 to 5 before contact inhibition occurred. At days 6 to 8, 
ODs slightly decreased probably due to a reduced meta-
bolic activity of cells that were grown to high density and 
exhaustion of nutrients in the medium (Fig. 1a). To deter-
mine the fraction of cells that were killed by the virus, ODs 
obtained from infected wells were subtracted from ODs 
observed from the uninfected control wells (Fig. 1b). The 
resulting delta OD (ΔOD) values were then used to calcu-
late the percentage of dead cells for each sample (Fig. 1c). 
This evaluation illustrates an increase in the percentage 
of dead cells with increasing ZIKV input and the time of 
infection (Fig. 1c).
The Vero E6 kidney epithelial cells extracted from Afri-
can green monkey are commonly used in ZIKV research, 
even they are not of human origin. To evaluate whether 
the MTT-based assay allows ZIKV detection in human 
cells, human osteosarcoma (HOS) cells were inoculated 
with serial dilutions of the ZIKV MR766 stock. The virus 
was cytopathogenic at days 3 and 4 post-infection which 
allows the quantification of remaining life cells by MTT 
assay (Fig. S3). As previously shown for Vero cells, the 
ODs inversely correlated with the amount of input virus 
(Fig. S3A and S3B), and allowed to calculate the percent-
age of cells that were killed by the virus (Fig. S3C). Thus, 
the MTT-based ZIKV CPE reduction assay can be easily 
adapted to human cells.
We next compared the sensitivity of the MTT-based 
cell viability assay with the one of the CellTiter-Glo® 
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Fig. 1  Representative results of the MTT-based assay to quantify 
ZIKV infection in Vero E6 cells. 6 × 103 Vero E6 cells were seeded 
in 96-well plates. The next day, 20  µl of serial tenfold dilutions 
of the ZIKV strain MR766 were added. After 1–8 days, cells were 
monitored microscopically and washed once with medium to remove 
detached virally infected cells. Thereafter, 20 µl of MTT was added to 
remaining adherent cells in 200 µl. After 3 h, formazan crystals were 
dissolved in DMSO/ethanol and absorbance of the colored solution at 
490 nm was quantified by a spectrophotometer. a Raw data obtained 
from live cells (optical densities; ODs) derived from triplicate infec-
tions ± standard deviation. b ODs derived from live cells in infected 
cell culture were subtracted from ODs obtained from uninfected con-
trol cells. The resulting ΔODs numbers provide an indirect value for 
all cells that detached due to virus infection. c Percentage of ZIKV-
induced cell death was calculated by normalizing the ΔOD values to 
the OD value of the uninfected control
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assays that determines intracellular levels of ATP by a 
luminescence-based reaction. The same assay principle has 
recently been used to screen for ZIKV inhibitors [25]. Here, 
we titrated ZIKV MR766 on Vero E6 cells and determined 
cell viabilities 4 days later by MTT (Fig. 2a) or CellTiter-
Glo® assay (Fig.  2b). Viral dilutions of  105 or higher did 
not result in reduced OD values (Fig.  2a) or luciferase 
activities (Fig.  2b). Infection with  101 and  102 dilutions 
of the virus caused pronounced cell death as observed 
by microscopy (data not shown), and consequently, only 
very low levels of formazan production (Fig. 2a) or lucif-
erase activity (Fig.  2b) were detected. Reduced viability 
rates were observed in wells infected with  103 to  104 dilu-
tions of the virus (Fig.  2a, b). To directly compare the 
sensitivity of both assays, we calculated the percentage 
of dead cells (Fig.  2c) as described above (Fig.  1c). As 
expected, both assays produced similar results (Fig.  2c). 
The signal-to-basal ratios of the MTT-based cell viability 
assay were approximately twofold higher than that of the 
CellTiter-Glo® assay (Fig.  2c) suggesting slightly higher 
sensitivity of the colorimetric assay. However, the Z’ fac-
tor of the luminescence-based assays was 0.91 and thus 
slightly higher than the Z’ factor for the MTT assays (0.77).
We next compared MTT-based ZIKV detection with a 
widely used immunofluorescence assay that utilized the pan 
anti-flavivirus mouse antibody 4G2 that binds ZIKV E pro-
tein [15, 26, 27]. Vero E6 cells were infected with the ZIKV 
MR766 strain and the MTT-based cell viability assay was 
performed after 1 and 2 days, and evaluated as described 
above (Fig.  3a). In parallel, cells were fixed, treated with 
the 4G2 antibody, washed, exposed to a secondary HRP-
coupled anti-mouse antibody, and washed again, before 
TMB substrate was added. Color development was stopped 
with sulfuric acid and ODs measured at 450 nm (Fig. 3b). 
As expected from data shown in Fig.  1, the ΔOD values 
measured by MTT assay increased from day 1 to 2 due to 
virus-induced CPE, and gradually declined with decreas-
ing amounts of input virus (Fig.  3a). When using the 
Fig. 2  Comparison of the 
colorimetric MTT test with the 
enzyme-linked CellTiter-Glo® 
Luminescent Cell Viabil-
ity Assay to quantify ZIKV 
infectivity. Vero E6 cells were 
infected with serial 10-fold 
dilutions of ZIKV MR766 and 
assayed 4 day post-infection 
using either a MTT assay or 
b the CellTiter-Glo® Lumi-
nescent Cell Viability Assay. 
Shown are mean OD values 
(a) or luciferase activities (b) 
derived from triple biological 
replicates ± standard deviation. 
c Direct comparison of both cell 
viability assays. The percentage 
of ZIKV-induced dead cells was 
calculated as described above. 
The numbers above the columns 
give the signal-to-noise ratios, 
i.e., the quotient of infected 
versus uninfected cells. C unin-
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antibody-based approach, the highest OD was obtained at 
day 1 in wells infected with the highest viral dose, and even 
inoculation with a  103 dilution of the virus resulted in a 
measurable OD signal (Fig. 3b). Because of plaque forma-
tion at day 2 in wells infected with the two highest viral 
doses, the ODs decreased  (101) or remained constant  (102), 
and spreading virus infection is likely the reason for the 
increase in OD values after inoculation with  103 and  104 
dilutions of the virus (Fig.  3b). Thus, the antibody-HRP 
based technique is more sensitive and allows detection of 
ZIKV as soon as 24 h post-infection. However, detachment 
of virally infected cells represents a confounding factor that 
needs to be taken into consideration when performing anti-
body-based readouts. The MTT-based assay that relies on 
the virus-induced CPE allows quantification of viral infec-
tivity at later time points and also over a broader range of 
viral inocula. This is a major advantage, because it allows 
analysis of multiple rounds of viral replication.
Having demonstrated that the MTT-based cell viability 
assay allows quantification of ZIKV infectivity, we next 
studied whether this assay could be adapted to determine 
the neutralizing antibody titers of well-characterized patient 
sera derived from confirmed Zika Virus Disease (ZVD) 
cases, and dengue virus (DENV) or tick-borne encephali-
tis virus (TBEV) infected individuals (Table  1). For this, 
 106  TCID50/ml of the ZIKV MR766 strain were incubated 
with serial dilutions of inactivated serum samples for 
90 min. Thereafter, 180 µl of Vero E6 cells were infected 
with 20 µl of ZIKV/antisera mixtures and the MTT-based 
cell viability assay was performed 4 days later. DENV and 
TBEV antisera modestly reduced the virus-induced CPE, 
but this effect is unlikely to be mediated by specific neu-
tralizing antibodies as two control sera displayed a similar 
activity (Fig.  4a). Interestingly, the four sera from ZVD 
patients inhibited ZIKV-induced cell death in a dose-
dependent manner (Fig. 4a, S4A). The most active serum 
was 6119 (Fig. 4a, S4A and B). Since the MTT assay yields 
values that can be processed electronically, we calculated 
the serum concentrations required to block ZIKV MR766 
infection by 50%  (IC50) or 80%  (IC80) using the Graph-
Pad Prism software. This analysis revealed that, e.g., 6119 
inhibited ZIKV infection with an  IC50 value of 0.013% and 
 IC80 of 0.059% (Table 2). The  IC50 values of the remaining 
ZIKV antisera were 0.043% (6635), 0.052% (8069), and 
0.10% (6636) (Table 2). Similarly, plotting ZIKV-induced 
cell death against antiserum dilutions (Fig. S4) allowed to 
calculate the titers to block infection by 50 or 80%, respec-
tively (Table  1). This analysis provides more exact quan-
titative values than those observed by classical readouts 
where only the last detected serum dilution is given (see 
IgM or IgG titers in Table 1) and where the titers are based 
on subjective plaque detection by eye (Table 1).
Thus, the MTT assay allows a rapid electronic deter-
mination of the neutralizing antibody titers (or inhibitory 
activities) without the need for a microscopic quantification 
of plaques performed in routinely used PRNT assays.
In all experiments, so far, we used the ZIKV strain 
MR766 that has been passaged in mice and cell culture 
multiple times [24]. We were wondering whether the 
MTT assay also allows analysis of a more recent clinical 
ZIKV isolate. For this, we used ZIKV FB-GWUH-2016 
that was derived post-mortem from the brain of a fetus 
with birth defects [20]. This isolate (termed GWUH 
herein) was passaged two times on Vero E6 cells where it 
also causes plaque formation (data not shown). We deter-
mined neutralizing antibody titers of all antisera against 
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Fig. 3  Comparison of the MTT- and a ZIKV immunodetection 
method. Vero E6 cells were infected with tenfold dilutions of ZIKV 
and after 1 or 2 days, viral infectivity was determined by a MTT 
assay (for better comparison, the ΔOD values are shown), or b immu-
nodetection with the ZIKV antibody 4G2. For this, cells were fixed, 
incubated with 4G2, washed, and then incubated with a secondary 
HRP-coupled antibody. After additional washing steps, TMB sub-
strate was added and color development quantified by ELISA plate 
reader. All values represent mean values ± standard deviation. C unin-
fected control
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the GWUH isolate under exactly the same conditions 
as for MR766. Again, we observed that control, DENV, 
and TBEV antisera slightly reduced plaque formation 
(Fig. 4b). Interestingly, only three of the four ZIKV anti-
sera (6119, 6635, and 8069) suppressed plaque formation 
by GWUH, whereas 6636 was almost inactive (Fig.  4b, 
Table 1  Characteristics and ZIKV neutralization of analyzed patient sera
IgM and IgG antibodies against DENV and TBEV were determined by indirect ELISA and are shown as indices (in italics). IgM and IgG anti-
bodies against ZIKV were determined by IIFT as described in material/methods section and give the titer (serum dilution) at which the fluores-
cence signal could last be detected. Control antisera were tested negative for anti-DENV IgM and IgG. The PRNT was performed with ZIKV 
MR766 and gives the titer (serum dilution) at which infected wells could be detected. The MTT-based assay allows calculation of titers (serum 
dilutions) at which ZIKV infection was blocked by 50 or 80%
Serum Designation IgM (index 
or titer)
IgG (index 
or titer)
PRNT (titer) MTT 50% inhibition MTT 80% inhibition
MR766 (titer) GWUH (titer) MR766 (titer) GWUH (titer)
Control A78269 0.1 0.3 <20 <100 <100 <100 <100
Control A78918 0.04 0.4 Nd <100 <100 <100 <100
DENV A62973 0.6 6.1 <20 <100 <100 <100 <100
DENV A64881 0.5 3.8 <20 <100 <100 <100 <100
DENV A69929 0.03 4.2 Nd <100 <100 <100 <100
TBEV A66845 0.17 5.5 <20 <100 <100 <100 <100
TBEV A77375 Nd 6.4 Nd <100 <100 <100 <100
ZIKV 6119 1280 2560 1280 6719 554 1586 <100
ZIKV 6635 2560 2560 3840 2195 1600 <100 172
ZIKV 6636 1280 320 960 747 <100 <100 <100
ZIKV 8069 1280 640 960 1764 164 199 <100
Fig. 4  MTT assay allows quan-
tification of the virus neutraliza-
tion capacity of antisera from 
ZVD patients. Negative control 
sera or sera positive for ZIKV 
(ZIKV+), Dengue (DENV+), 
or tick-borne encephalitis virus 
(TBEV+) IgG and IgM antibod-
ies (Table 1) were diluted and 
incubated for 90 min with 
1 × 106  TCID50/ml of the lab-
adapted ZIKV strain MR766 
(a) or the recent clinical isolate 
GWUH (b). Thereafter, 180 µl 
Vero E6 cells were infected 
with 20 µl of the virus/antisera 
samples, and 4 days later MTT 
assay was performed. Shown is 
the percentage of virus-induced 
dead cells obtained from 
triplicate infections ± standard 
deviation. Shown on the x-axis 
are the final cell culture concen-
trations of the sera in %
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S4C and S4D). In general, the MTT-IC50 values against 
GWUH were slightly higher as compared to MR766 
(Tables 1, 2, Fig. S4C and S4D). Taken together, our data 
show that the MTT-based cell viability assay not only 
allows quantification of ZIKV neutralizing antibody titers 
but may also detect differences in the antibody response 
against ZIKV lineages.
Finally, we analyzed whether the MTT assay can be 
used to study inhibitors of ZIKV infection or replica-
tion. For this, Vero E6 cells were exposed to IFN-α which 
inhibits ZIKV infection [15], and were then inoculated 
with ZIKV GWUH. The MTT assay detected a dose-
dependent suppression of ZIKV-induced cell death by 
IFN-α (Fig.  5). Thus, the MTT-based ZIKV detection 
assay allows studying antivirals and might be particularly 
useful for larger high-throughput screening approaches.
Discussion
We describe, in this report, a reliable, robust, and cheap 
assay to determine ZIKV infectivity and its neutralization 
by antisera or suppression by antivirals. Our test is based 
on the ZIKV-induced cytopathic effects that result in cell 
death and cellular detachment which is indirectly quantified 
by measuring the metabolic activity of remaining adher-
ent life cells. We show that the MTT-based viability assay 
has a very broad dynamic range (Fig. 1, S2 and S3) and an 
excellent Z’ factor. Moreover, MTT ODs (and hence, ZIKV 
-induced cell death) almost perfectly correlated with the 
viral inoculum (Fig. 1 and S2). At later time points, sigmoi-
dal dose–response curves were obtained due to pronounced 
cell death caused by spreading infection in infected wells, 
whereas cells in uninfected wells remained alive (Fig. S2). 
However, ODs are derived from live (non-infected) cells. 
To define the percentage of cells that were killed by ZIKV, 
we calculated ΔOD values by subtracting ODs derived 
from uninfected cells from ODs from infected cells and 
normalized these data for viable cells in the untreated con-
trol. These values represent the percentage of cells that 
were killed by ZIKV and provide a more direct value for 
viral infectivity (Figs. 1, 2, and S3) or its inhibition by anti-
sera (Fig. 4, S4) or interferon (Fig. 5).
The infectious titer of ZIKV is usually determined by 
 TCID50 analysis using endpoint titrations and microscopic 
evaluation of the virus-induced CPE between 5 and 10 
days post-inoculation [17, 28]. However, microscopy of 
virus-induced plaques requires experienced personnel and 
is laborious, in particular when a large number of samples 
have to be analyzed. Thus, we were wondering whether the 
MTT assay may provide an alternative methodology that 
allows for a more convenient analysis of infectious viral 
titers. For this, we have taken the data set obtained at day 8 
post-infection (Fig. 1a) and calculated the  TCID50 accord-
ing to Reed and Munch [29]. Wells were defined as infected 
if the OD was decreased by more than three times of the 
standard deviation of uninfected wells. This resulted in 
the calculation of an MTT  TCID50 of 1.2 × 107/ml, which 
is in good accordance with the  TCID50 obtained by micro-
scopic plaque detection, which was 1.7 × 107/ml [7]. Thus, 
the MTT assay allows fast and quantitative determination 
of the infectious ZIKV titer without the need for time-con-
suming microscopy.
Colorimetric quantification of virus-induced cell killing 
by MTT had been used before to determine titers of influ-
enza virus [30], picornaviruses [31], or respiratory syncy-
tial virus [32]. In addition, this assay has been adapted to 
measure the efficacy of antivirals against HIV-1 [33–35], or 
herpes viruses [36, 37] or to perform vaccinia virus neutral-
ization tests (VNT) [38]. Since ZIKV neutralizing antibody 
titers have usually been determined by microscopy-based 
Table 2  50 and 80% inhibitory concentrations of ZKD sera against 
ZIKV
Values shown were calculated using GraphPad Prism
Antiserum Designation IC50 IC80
% serum in cell culture (v/v)
MR766 GWUH MR766 GWUH
ZIKV 6119 0.013 0.172 0.059 >1
ZIKV 6635 0.043 0.056 0.410 1
ZIKV 6636 0.100 >1 >1 >1
ZIKV 8069 0.052 0.442 >1 >1
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Fig. 5  Interferon α inhibits ZIKV GWUH infection as shown by 
MTT assay. Vero E6 (170 µl) cells were incubated with 10 µl IFN-α 
at indicated concentrations for 2 h, before 20 µl ZIKV strain GWUH 
was added. 3 days later, MTT assay was performed. Shown is the 
percentage of virus-induced cell death obtained from triplicate infec-
tions ± standard deviation
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time-consuming PRNT, we were wondering whether the 
MTT-based VNT could provide an alternative. Our results 
show that the four antisera derived from acute ZVD cases 
dose-dependently suppressed cell killing allowing a con-
venient determination of half maximal effective concentra-
tions (Fig. 4; Tables 1, 2). These antisera have previously 
been analyzed in the IIFA for anti-ZIKV-IgM and IgG. 
There seems to be a correlation between anti-ZIKV IgG 
titers with MTT  EC50s measured in the VNT assays, but the 
small sample size does not allow a statistical meaningful 
analysis. However, the use of two different ZIKV strains in 
the MTT-based VNT resulted in different titers. This find-
ing suggests that the assay may allow the serological dis-
crimination of ZIKV African and Asian lineage-specific 
antibody responses, or to study possible differences in 
neutralization capacities to pathogenic versus less patho-
genic ZIKV strains. Therefore, more ZIKV African and 
Asian lineage-specific antisera should be analyzed in the 
MTT-based VNT to further support these initial findings. 
In addition, cross-neutralizing flavivirus antibodies were 
frequently detected in PRNTs. In contrast, our MTT-based 
VNT  was demonstrated to be highly specific and, thus, 
eliminates the need for parallel testing with other flavivi-
ruses to exclude the serological cross-reactivities. Further-
more, the dose-dependent reduction of infection by the 
natural ZIKV inhibitor IFN-α (Fig.  5) suggests that the 
MTT assay can be applied for high-throughput screening 
for ZIKV inhibitors.
The prerequisite for the MTT-based detection of viral 
infection is the capacity of the virus to induce cell death. 
We have tested the cell culture adapted ZIKV strain MR766 
and the clinical isolate GWUH, and found that both induce 
pronounced cytopathic effects in Vero E6 monolayers. 
Many other ZIKV isolates were reported to be cytopathic 
likely allowing their analyses by MTT assay [39–43]. We 
have established the protocol using Vero E6 cells, a kidney 
cell line derived from an African green monkey that exhib-
its some degree of contact inhibition after forming a mon-
olayer. This is useful in growing slow replicating viruses 
or determining neutralization titers that are directed against 
the virus, but has some limitations, because the cells are not 
of human origin. For example, cellular receptors involved 
in ZIKV entry and replication may differ between African 
green monkey and human cells. However, ZIKV has also 
been described as cytopathogenic in human cell cultures 
[44–46]. In fact, our results show that ZIKV causes cellu-
lar detachment of HOS monolayers, and consequently, the 
MTT-based assay could be easily adapted to human cells 
(Fig. S3).
In general, every cell viability assay can be adapted to 
quantify virus-induced cell killing. For example, Zmurko 
et al. recently made use of the soluble MTS reagent [23] 
and Xu et  al. applied a luminescence-based assay that 
measures intracellular ATP to study the effect of antivi-
rals on ZIKV infection [47]. We here compared the later 
assay principle with the MTT assay, and obtained Z’ fac-
tors and signal-to-basal (S/B) ratios in the same dynamic 
range (Fig.  2). Thus, the MTT assay is a reasonable 
alternative to the more costly luminescence-based read-
out. Another cell viability assay that has been adapted to 
quantify virus-induced CPE is based on the reduction of 
resazurin dye to the fluorescent resorufin product in met-
abolically active cells. This assay has been developed to 
determine the infectious dose of influenza virus strains 
[48] and does not require solubilization of the prod-
uct. Similarly, tetrazolium salts, such as XTT or MTS, 
have been developed that are reduced to water soluble 
formazan derivatives and do not require solubilization 
with organic solvents for absorbance measurement. This 
is in contrast to the insoluble formazan crystals that form 
in the MTT assay. This advantage of resazurin or XTT/
MTS-based assays is, however, a disadvantage for our 
assay, because it would require an additional decontami-
nation step to inactivate ZIKV. Addition of the DMSO/
ethanol solution to solubilize formazan inactivates ZIKV 
[7] and thus allows measuring absorbance of microtiter 
plates without the risk of infection.
Finally, the key advantage of the MTT assay is its 
low prize. The results can be monitored directly by the 
naked eye (Fig. S1B), and quantification can easily be 
performed in normal plate readers that are far cheaper 
than luminometers or fluorimeters. In addition, the MTT 
salt itself is at least 50 times cheaper than XTT, MTS, 
or luminescence-based cell viability kits. We calculated 
the material costs for one MTT assay per well with ~2 
cents, which corresponds to only ~US$2 per 96-well 
plate. Thus, the MTT assay is a promising alternative 
to determine ZIKV titers or its inhibition by antisera or 
antivirals, in particular for large sample numbers under 
resource-poor settings.
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